Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure

AIDS

Volumn 18, Issue 12, 2004, Pages 11-19

  Ceccherini Silberstein, Francesca ^a   Erba, Fulvio ^a   Gago, Federico ^b   Bertoli, Ada ^a   Forbici, Federica ^c   Bellocchi, Maria Concetta ^c   Gori, Caterina ^c   D'Arrigo, Roberta ^c   Marcon, Luisa ^d   Balotta, Claudia ^e   Antinori, Andrea ^c   D'Arminio Monforte, Antonella ^e   Perno, Carlo Federico ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiretroviral therapy; Conservation; Genotype; HIV drug resistance; Protease; Resistance mutations

Indexed keywords

AMPRENAVIR; DIMER; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD ANALYSIS; CARBOXY TERMINAL SEQUENCE; CATALYSIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME STRUCTURE; GENETIC CONSERVATION; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN VARIANT; VIRAL GENETICS; VIRUS MUTATION;

AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; CONSERVED SEQUENCE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, CHEMICAL; MODELS, GENETIC; MUTATION; POLYMORPHISM, GENETIC;

EID: 4143099182     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131394.76221.02     Document Type: Article

References (51)

1. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
2. Perrin L, Kaiser L, Yerly S. Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003, 3:22-27.
3. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
4. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
5. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003, 17:791-799.
6. Hertogs K, Bloor S, Kemp SD, Van den Eyncle C, Alcorn TM, Pauwels R, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000, 14:1203-1210.
7. Shafer RW, Stevenson D, Chan B. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucl Acids Res 1999, 27:348-352.
8. Flexner CW. HIV-protease inhibitors. New Engl J Med 1998, 338:1281-1292.
9. Huff JK. HIV protease: a novel chemotherapeutic target for AIDS. J Med Chem 1991, 34:2305-2314.
10. Rodriguez-Barrios F, Gago F. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls. Curr Top Med Chem 2004, 4:671-686.
11. Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 1993, 62:543-585.
12. Alexander CS, Dong W, Chan K, Jahnke N, O'Shaughnessy MV, Mo T, et al. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 2001, 15:601-607.
13. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282:1135-1141.
14. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001, 15:1493-1502.
15. Gonzales MJ, Machekano RN, Shafer RW. Human immu-nodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 2001, 184:998-1006.
16. Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, Burke M, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 2001, 15:1453-1460.
17. Kozal MJ, Shah N, Shen NP, Yang K, Fucini R, Merigan TC, et al. Extensive polymorphisms observed in HIV-1 clade-B protease gene using high-density oligonucleotide arrays. Nat Med 1996, 2:753-759.
18. Lech WJ, Wang G, Yang YL, Chee Y, Dorman K, McCrae D, et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
19. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. New Engl J Med 2002, 347:385-394.
20. Perno CF, Cozzi-Lepri A, Balotta C, Bertoli A, Violin M, Monno L, et al. Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS 2002, 16:619-624.
21. Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001, 184:983-991.
22. Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000, 14:1489-1495.
23. Ribeiro RM, Bonhoeffer S, Nowak MA. The frequency of resistant mutant virus before antiviral therapy. AIDS 1998, 12:461-465.
24. Verbiest W, Brown S, Cohen C, Conant M, Henry K, Hunt S, et al. Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study. AIDS 2001, 15:647-650.
25. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003, 77:4836-4847.
26. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354:729-733.
27. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003, 11:215-221.
28. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000, 283:2417-2426.
29. Schinazi RF, Larder BA, Mellors I. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antiviral News 2000, 8:65-91.
30. Stanford HIV sequence database 2002: http://hivrib.Stanford.edu.
31. Fontenot G, Johnston K, Cohen IC, Gallaher WR, Robinson J, Luftig RB. PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains. Virology 1992, 190:1-10.
32. Winslow DL, Stack S, King R, Scarnati H, Bincsik A, Otto MJ. Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res Hum Retroviruses 1995, 11:107-113.
33. Wang W, Kollman PA. Computational study of protein specifmanicity: the molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci USA 2001, 98:14937-14942.
34. ClustalW: http://www.ebi.ac.uk.
35. Guex N, Peitsch MC. Swiss-model and the Swiss-PdbViewer: an environment for comparative protein modelling. Electrophoresis 1997, 18:2714-2723.
36. Priestle JP, Fassler A, Rosel J, Tintelnot-Blomley M, Strop P, Grutter MG. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure 1995, 3:381-389.
37. Weber IT. Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J Biol Chem 1990, 265:10492-10496.
38. Wlodawer A, Gustchina A. Structural and biochemical studies of retroviral proteases. Biochim Biophys Acta 2000, 1477:16-34.
39. Wlodawer A, Miller M, Jaskolski M, Sathyanarayana BK, Baldwin E, Weber JT, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989, 245:616-621.
40. Olsen DB, Stahlhut MW, Rutkowski CA, Schock HB, vanOlden AL, Kuo LC. Non-active-site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. J Biol Chem 1999, 274:23699-23701.
41. Martinez-Picado J, Savara AV, Shi L, Sutton L, D'Aquila RT. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000, 275:318-322.
42. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999, 73:3744-3752.
43. Scott WR, Schiffer CA. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Struct Fold Des 2000, 8:1259-1265.
44. Todd MJ, Semo N, Freire E. The structural stability of the HIV-1 protease. J Mol Biol 1998, 283:475-488.
45. Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, Hutchison CA III. Complete mutagenesis of the HIV-1 protease. Nature 1989, 340:397-400.
46. Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998, 72:7532-7541.
47. Colonno RI, Thiry A, Limoli K, Parkin N. Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors. Antimicrob Agents Chemother 2003, 47:1324-1333.
48. Ho DD, Toyoshima T, Mo H, Kempf DJ, Norbeck D, Chen CM, et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol 1994, 68:2016-2020.
49. Maguire M, Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002, 46:731-738.
50. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to 150V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002, 76:7398-7406.
51. Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, et al. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active-site. J Virol 2002, 76:1349-1358.